Sevelamer Carbonate Tablets

Guidelines recommend first-line drugs for the clinical treatment of hyperphosphatemia in adults with chronic kidney disease(CKD)

In recent years, the incidence and hospitalization rate of chronic kidney disease 〔CKD〕, especially end-stage renal disease, have increased significantly, seriously threatening human health. Sevelamer carbonate is a new generation of non-absorbable phosphate-binding crosslinked polymers, which can reduce the concentration of phosphate in serum by binding to phosphate in the digestive tract and reducing its absorption. It is clinically used to control hyperphosphatemia in adult patients with chronic kidney disease 〔CKD〕 undergoing dialysis treatment and is the first-line drug recommended by clinical treatment guidelines.

Indications:

Sevelamer carbonated Tablets are indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.

STRENGTH:

800mg/Film-coated Tablets